Retrospective Cohort Study
Copyright ©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Oct 15, 2018; 9(10): 165-171
Published online Oct 15, 2018. doi: 10.4239/wjd.v9.i10.165
Efficacy of anagliptin as compared to linagliptin on metabolic parameters over 2 years of drug consumption: A retrospective cohort study
Hidetaka Hamasaki, Yasuteru Hamasaki
Hidetaka Hamasaki, Endocrinology and Metabolism, Internal Medicine, Hamasaki Clinic, Kagoshima 890-0046, Japan
Yasuteru Hamasaki, Diabetes, Hamasaki Clinic, Kagoshima 890-0046, Japan
Author contributions: Hamasaki H and Hamasaki Y equally contributed to study conception, data acquisition, data analysis, interpretation, and writing of article.
Institutional review board statement: This study protocol was reviewed and approved by the Japan Medical Association Ethical Review Board.
Informed consent statement: Study participants are assured that collected data will be used only for this study and will not be disclosed without the consent of the participants.
Conflict-of-interest statement: The authors declare no conflict of interest.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Hidetaka Hamasaki, MD, PhD, Doctor, Endocrinology and Metabolism, Internal Medicine, Hamasaki Clinic, Nishida 2-21-4, Kagoshima 890-0046, Japan. hhamasaki78@gmail.com
Telephone: +81-99-2503535 Fax: +81-99-2501470
Received: June 25, 2018
Peer-review started: June 25, 2018
First decision: July 9, 2018
Revised: July 12, 2018
Accepted: August 26, 2018
Article in press: August 26, 2018
Published online: October 15, 2018
Processing time: 110 Days and 7.6 Hours
Core Tip

Core tip: Whether a substantial clinical difference exists in the effect of dipeptidyl peptidase-4 (DPP-4) inhibitors on metabolic parameters remains inconclusive. Although this study is a relatively small-scale, short duration, retrospective study, the findings of this study suggests that the efficacy of DPP-4 inhibitors on the blood pressure, lipid profile, and liver function differs between anagliptin and linagliptin.